The Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade - Wassim Abida

January 31, 2019

Wassim Abida joins Charles Ryan in a discussion on a JAMA Oncology published paper on the Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. Wassim details the prevalence of MSI-H/dMMR prostate cancer and the clinical benefit of anti–PD-1/programmed cell death 1 ligand 1 (PD-L1) therapy in this molecularly defined population. The discussion includes the therapeutic approach to treatment and the role of panel sequencing, the feasibility of finding BRCA mutations, and possible reasons for MSI high patients to not respond to immunotherapy.

Biographies:
Wassim Abida, MD, Ph.D. Medical Oncologist, Memorial Sloan Kettering Cancer Center

Charles J. Ryan, MD is the B.J. Kennedy Chair in Clinical Medical Oncology at the University of Minnesota and Director of the Division of Hematology, Oncology, and Transplantation.